AU2020290516B2 - Compositions and methods for biological delivery vehicles - Google Patents
Compositions and methods for biological delivery vehiclesInfo
- Publication number
- AU2020290516B2 AU2020290516B2 AU2020290516A AU2020290516A AU2020290516B2 AU 2020290516 B2 AU2020290516 B2 AU 2020290516B2 AU 2020290516 A AU2020290516 A AU 2020290516A AU 2020290516 A AU2020290516 A AU 2020290516A AU 2020290516 B2 AU2020290516 B2 AU 2020290516B2
- Authority
- AU
- Australia
- Prior art keywords
- delivery vehicle
- lipid
- mole
- glycero
- cationic lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
- A61K47/6909—Micelles formed by phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861852P | 2019-06-14 | 2019-06-14 | |
| US62/861,852 | 2019-06-14 | ||
| US201962948095P | 2019-12-13 | 2019-12-13 | |
| US62/948,095 | 2019-12-13 | ||
| PCT/US2020/037579 WO2020252375A1 (en) | 2019-06-14 | 2020-06-12 | Compositions and methods for biological delivery vehicles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2020290516A1 AU2020290516A1 (en) | 2022-01-20 |
| AU2020290516A2 AU2020290516A2 (en) | 2022-03-31 |
| AU2020290516B2 true AU2020290516B2 (en) | 2026-01-29 |
Family
ID=73781318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020290516A Active AU2020290516B2 (en) | 2019-06-14 | 2020-06-12 | Compositions and methods for biological delivery vehicles |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220296516A1 (https=) |
| EP (1) | EP3982932A4 (https=) |
| JP (1) | JP7772597B2 (https=) |
| CN (1) | CN114286671A (https=) |
| AU (1) | AU2020290516B2 (https=) |
| CA (1) | CA3142949A1 (https=) |
| IL (1) | IL288755A (https=) |
| WO (1) | WO2020252375A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| US20230023615A1 (en) * | 2019-12-13 | 2023-01-26 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| WO2022260678A1 (en) * | 2021-06-11 | 2022-12-15 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| EP4259099A1 (en) * | 2020-12-14 | 2023-10-18 | Particella, Inc. | Biological delivery systems |
| US20240050477A1 (en) * | 2021-02-17 | 2024-02-15 | National University Corporation Hokkaido University | Lipid nanoparticle |
| US20240358651A1 (en) * | 2021-04-01 | 2024-10-31 | Snj Pharma Inc | Oral nanoparticles for bioactive compound, and method of preparing same |
| KR102789632B1 (ko) * | 2021-04-01 | 2025-04-01 | 에스엔제이 파마 인크 | 생활성물질의 경구용 나노입자 및 이의 제조방법 |
| KR20230141513A (ko) * | 2022-03-22 | 2023-10-10 | 주식회사 바이오엔 | 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도 |
| CN117247359A (zh) * | 2022-06-09 | 2023-12-19 | 中国科学院广州生物医药与健康研究院 | 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用 |
| WO2024006863A1 (en) * | 2022-06-30 | 2024-01-04 | Precision NanoSystems ULC | Lipid nanoparticle formulations for vaccines |
| CN118356505A (zh) * | 2023-01-10 | 2024-07-19 | 复旦大学 | 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途 |
| CN121443279A (zh) * | 2023-06-28 | 2026-01-30 | 环球生命科学解决方案加拿大有限公司 | 用于细胞疗法的脂质纳米颗粒制剂和相关方法 |
| WO2025021286A1 (en) * | 2023-07-23 | 2025-01-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | A drug delivery system for increased endosomal escape |
| CN121752254A (zh) * | 2023-08-11 | 2026-03-27 | 浙江海昶生物医药股份有限公司 | 一种具有靶向性的脂质组合物及其制备方法 |
| US20250082776A1 (en) * | 2023-08-31 | 2025-03-13 | Massachusetts Institute Of Technology | Polyanion coated lipid nanoparticles and methods of use thereof |
| PL248770B1 (pl) * | 2023-11-23 | 2026-01-26 | Politechnika Wroclawska | Bilosomy o dodatnim ładunku i sposób ich wytwarzania |
| WO2025151073A1 (en) * | 2024-01-10 | 2025-07-17 | Agency For Science, Technology And Research | Composition and nanoparticle suitable for use in the delivery of a therapeutic agent |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100239657A1 (en) * | 2006-11-09 | 2010-09-23 | Mogam Biotechnology Research Institute | Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs |
| WO2010149785A1 (en) * | 2009-06-26 | 2010-12-29 | Universiteit Gent | Cationic liposomes for the delivery of high molecular weight compounds |
| WO2011075656A1 (en) * | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
| WO2012113803A1 (en) * | 2011-02-22 | 2012-08-30 | Leo Pharma A/S | A cyclic peptide and conjugate thereof for binding to keratinocytes |
| WO2016070082A1 (en) * | 2014-10-31 | 2016-05-06 | University Of Utah Research Foundation | Compositions and methods for bile acid particles |
| WO2018078053A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018509387A (ja) * | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
| EP3675817A1 (en) * | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
-
2020
- 2020-06-12 EP EP20821834.7A patent/EP3982932A4/en active Pending
- 2020-06-12 CN CN202080056429.6A patent/CN114286671A/zh active Pending
- 2020-06-12 JP JP2021573887A patent/JP7772597B2/ja active Active
- 2020-06-12 AU AU2020290516A patent/AU2020290516B2/en active Active
- 2020-06-12 CA CA3142949A patent/CA3142949A1/en active Pending
- 2020-06-12 WO PCT/US2020/037579 patent/WO2020252375A1/en not_active Ceased
- 2020-06-12 US US17/619,036 patent/US20220296516A1/en active Pending
-
2021
- 2021-12-07 IL IL288755A patent/IL288755A/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100239657A1 (en) * | 2006-11-09 | 2010-09-23 | Mogam Biotechnology Research Institute | Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs |
| WO2010149785A1 (en) * | 2009-06-26 | 2010-12-29 | Universiteit Gent | Cationic liposomes for the delivery of high molecular weight compounds |
| WO2011075656A1 (en) * | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
| WO2012113803A1 (en) * | 2011-02-22 | 2012-08-30 | Leo Pharma A/S | A cyclic peptide and conjugate thereof for binding to keratinocytes |
| WO2016070082A1 (en) * | 2014-10-31 | 2016-05-06 | University Of Utah Research Foundation | Compositions and methods for bile acid particles |
| WO2018078053A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
Non-Patent Citations (4)
| Title |
|---|
| JITINDER S WIKHU , SARAH E MCNEIL , DAVID E ANDERSON , YVONNE PERRIE : "Characterization and optimization of bilosomes for oral vaccine delivery", JOURNAL OF DRUG TARGETING, TAYLOR & FRANCIS, GB, vol. 21, no. 3, 30 November 2012 (2012-11-30), GB, pages 291 - 299, XP009532436, ISSN: 1061-186X, DOI: 10.3109/1061186X.2012.747528 * |
| MONALISA MOHAPATRA, ASHOK K. MISHRA: "Effect of Submicellar Concentrations of Conjugated and Unconjugated Bile Salts on the Lipid Bilayer Membrane", LANGMUIR, AMERICAN CHEMICAL SOCIETY, vol. 27, no. 22, 15 November 2011 (2011-11-15), pages 13461 - 13467, XP055771017, ISSN: 0743-7463, DOI: 10.1021/la203028s * |
| SCHWENDENER RETO A.: "Liposomes as vaccine delivery systems: a review of the recent advances", THER ADV VACCINES, 1 January 2014 (2014-01-01), pages 159 - 182, XP055874534, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/2051013614541440> [retrieved on 20211220], DOI: 10.1177/2051013614541440Therapeutic * |
| TANVI RAJPUT, TANVI RAJPUT, MEENAKSHI CHAUHAN: "BILOSOME: A BILE SALT BASED NOVEL CARRIER SYSTEM GAINING INTEREST IN PHARMACEUTICAL RESEARCH", JOURNAL OF DRUG DELIVERY AND THERAPEUTICS, VINITA NAGAR, vol. 7, no. 5, 15 September 2017 (2017-09-15), pages 4 - 16, XP055771018, ISSN: 2250-1177, DOI: 10.22270/jddt.v7i5.1479 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7772597B2 (ja) | 2025-11-18 |
| WO2020252375A1 (en) | 2020-12-17 |
| JP2022538797A (ja) | 2022-09-06 |
| AU2020290516A1 (en) | 2022-01-20 |
| CN114286671A (zh) | 2022-04-05 |
| AU2020290516A2 (en) | 2022-03-31 |
| IL288755A (en) | 2022-02-01 |
| EP3982932A1 (en) | 2022-04-20 |
| EP3982932A4 (en) | 2023-10-25 |
| US20220296516A1 (en) | 2022-09-22 |
| CA3142949A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020290516B2 (en) | Compositions and methods for biological delivery vehicles | |
| US20230023615A1 (en) | Compositions and methods for biological delivery vehicles | |
| WO2022260678A1 (en) | Compositions and methods for biological delivery vehicles | |
| JP3907662B2 (ja) | 自己構築ポリヌクレオチド送達システム | |
| JP2021050212A (ja) | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム | |
| US20240058454A1 (en) | Biological delivery systems | |
| TW201019969A (en) | Branched cationic lipids for nucleic acids delivery system | |
| US20190351071A1 (en) | Structures and methods for gene therapy | |
| US20240197636A1 (en) | Tissue-specific nucleic acid delivery by mixed cationic lipid particles | |
| US20210177982A1 (en) | Mucus-penetrating peptides, delivery vehicles and methods of therapy | |
| US20250041325A1 (en) | Lipid-based compositions and methods thereof | |
| KR20250134181A (ko) | 핵산의 표적화된 전달을 위한 상승된 중성 지질 및 표적화 모이어티를 포함하는 지질 나노입자 | |
| US20240269318A1 (en) | Nano-delivery systems comprising modified lipids and use thereof | |
| US20160038597A9 (en) | Carrier that targets fucosylated molecule-producing cells | |
| JP5615509B2 (ja) | フコシル化糖鎖産生細胞用物質送達担体 | |
| CN117241780A (zh) | 生物递送系统 | |
| JP5871247B2 (ja) | フコシル化糖鎖産生細胞用物質送達担体 | |
| KR20250141812A (ko) | Rna에 대한 선천성 면역 반응을 감소시키기 위한 방법 및 변형 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 14 MAR 2022 |